{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T11:09:54Z","timestamp":1773486594742,"version":"3.50.1"},"reference-count":93,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.3892\/or.2015.4456","type":"journal-article","created":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T10:02:01Z","timestamp":1448532121000},"page":"614-624","source":"Crossref","is-referenced-by-count":35,"title":["The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review)"],"prefix":"10.3892","volume":"35","author":[{"given":"CARLA","family":"DI STEFANO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GIOVANNA","family":"MIRONE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"STEFANIA","family":"PERNA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GABRIELLA","family":"MARFE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,11,26]]},"reference":[{"key":"key20180107211143_b1-or-35-02-0614","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"key20180107211143_b2-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C","article-title":"Characteristics of accelerated disease in chronic myelogenous leukemia","volume":"61","author":"Kantarjian","year":"1988","journal-title":"Cancer"},{"key":"key20180107211143_b3-or-35-02-0614","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","article-title":"Chronic myelogenous leukemia: A concise update","volume":"82","author":"Kantarjian","year":"1993","journal-title":"Blood"},{"key":"key20180107211143_b4-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1126\/science.144.3623.1229","article-title":"DNA contents of chromosome Ph1 and chromosome 21 in human chronic granulocytic leukemia","volume":"144","author":"Rudkin","year":"1964","journal-title":"Science"},{"key":"key20180107211143_b5-or-35-02-0614","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"key20180107211143_b6-or-35-02-0614","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2141.2001.02558.x","article-title":"Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: Lessons to be learned from the laboratory","volume":"113","author":"Holyoake","year":"2001","journal-title":"Br J Haematol"},{"key":"key20180107211143_b7-or-35-02-0614","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.V94.7.2452.419k23_2452_2460","article-title":"ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia","volume":"94","author":"Asimakopoulos","year":"1999","journal-title":"Blood"},{"key":"key20180107211143_b8-or-35-02-0614","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/jcb.24154","article-title":"Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia","volume":"113","author":"Mancini","year":"2012","journal-title":"J Cell Biochem"},{"key":"key20180107211143_b9-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s13277-011-0222-1","article-title":"Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells","volume":"32","author":"Huang","year":"2011","journal-title":"Tumour Biol"},{"key":"key20180107211143_b10-or-35-02-0614","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","volume":"1","author":"Bixby","year":"2009","journal-title":"HHematology Am Soc Hematol Educ Program"},{"issue":"23","key":"key20180107211143_b11-or-35-02-0614","article-title":"Bcr-Abl tyrosine kinase inhibitors - current status","volume":"8","author":"Mughal","year":"2013","journal-title":"Infect Agent Cancer"},{"key":"key20180107211143_b12-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.bmcl.2005.11.042","article-title":"Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors","volume":"16","author":"Asaki","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"key20180107211143_b13-or-35-02-0614","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ceb.2009.01.014","article-title":"The interplay of structural information and functional studies in kinase drug design: Insights from BCR-Abl","volume":"21","author":"Eck","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"key20180107211143_b14-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review","volume":"34","author":"An","year":"2010","journal-title":"Leuk Res"},{"key":"key20180107211143_b15-or-35-02-0614","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.clinthera.2010.05.003","article-title":"Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib","volume":"32","author":"Stein","year":"2010","journal-title":"Clin Ther"},{"key":"key20180107211143_b16-or-35-02-0614","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: Implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"key20180107211143_b17-or-35-02-0614","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CE.S6003","article-title":"Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review","volume":"4","author":"Jabbour","year":"2009","journal-title":"Core Evid"},{"key":"key20180107211143_b18-or-35-02-0614","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 6","key":"key20180107211143_b19-or-35-02-0614","doi-asserted-by":"crossref","first-page":"vi42","DOI":"10.1093\/annonc\/mdm223","article-title":"Dasatinib: A new step in molecular target therapy","volume":"18","author":"Olivieri","year":"2007","journal-title":"Ann Oncol"},{"key":"key20180107211143_b20-or-35-02-0614","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"key20180107211143_b21-or-35-02-0614","unstructured":"FDA Drug Safety CommunicationFDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales. U.S. Food and Drug Administration2013http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm373040.htm. Accessed Nov 26, 2013"},{"key":"key20180107211143_b22-or-35-02-0614","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40272-014-0085-1","article-title":"Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers","volume":"16","author":"Lipshultz","year":"2014","journal-title":"Paediatr Drugs"},{"key":"key20180107211143_b23-or-35-02-0614","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"key":"key20180107211143_b24-or-35-02-0614","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.bmcl.2007.03.002","article-title":"Structural factors contributing to the Abl\/Lyn dual inhibitory activity of 3-substituted benzamide derivatives","volume":"17","author":"Horio","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"key20180107211143_b25-or-35-02-0614","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1365-2362.2010.02328.x","article-title":"Standard treatment of Ph+ CML in 2010: How, when and where not to use what BCR\/ABL1 kinase inhibitor?","volume":"40","author":"Valent","year":"2010","journal-title":"Eur J Clin Invest"},{"key":"key20180107211143_b26-or-35-02-0614","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/B978-0-12-387038-4.00009-4","article-title":"Biological robustness and the role of microRNAs: A network perspective","volume":"99","author":"Pel\u00e1ez","year":"2012","journal-title":"Curr Top Dev Biol"},{"key":"key20180107211143_b27-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.molcel.2014.02.013","article-title":"Global analyses of the effect of different cellular contexts on microRNA targeting","volume":"53","author":"Nam","year":"2014","journal-title":"Mol Cell"},{"key":"key20180107211143_b28-or-35-02-0614","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-pathol-012513-104715","article-title":"MicroRNAs in cancer","volume":"9","author":"Di Leva","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"key20180107211143_b29-or-35-02-0614","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The heterochronic gene lin-4 of C. elegans encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"key20180107211143_b30-or-35-02-0614","doi-asserted-by":"crossref","first-page":"D152","DOI":"10.1093\/nar\/gkq1027","article-title":"miRBase: Integrating microRNA annotation and deep-sequencing data","volume":"39","author":"Kozomara","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"key20180107211143_b31-or-35-02-0614","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1440-1681.2009.05269.x","article-title":"MicroRNAs in common diseases and potential therapeutic applications","volume":"37","author":"Tsai","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"key20180107211143_b32-or-35-02-0614","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs - microRNAs with a role in cancer","volume":"6","author":"Esquela-Kerscher","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"key20180107211143_b33-or-35-02-0614","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.bbrc.2007.10.077","article-title":"Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis","volume":"364","author":"Masaki","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107211143_b34-or-35-02-0614","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1158\/0008-5472.CAN-09-0309","article-title":"Cell cycle regulation by microRNAs in embryonic stem cells","volume":"69","author":"Wang","year":"2009","journal-title":"Cancer Res"},{"key":"key20180107211143_b35-or-35-02-0614","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jcp.22066","article-title":"MicroRNAs as gatekeepers of apoptosis","volume":"223","author":"Subramanian","year":"2010","journal-title":"J Cell Physiol"},{"key":"key20180107211143_b36-or-35-02-0614","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0092-8674(03)00759-1","article-title":"Asymmetry in the assembly of the RNAi enzyme complex","volume":"115","author":"Schwarz","year":"2003","journal-title":"Cell"},{"key":"key20180107211143_b37-or-35-02-0614","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.molcel.2007.09.028","article-title":"Mammalian mirtron genes","volume":"28","author":"Berezikov","year":"2007","journal-title":"Mol Cell"},{"key":"key20180107211143_b38-or-35-02-0614","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/1471-2164-11-533","article-title":"A potential role for intragenic miRNAs on their hosts' interactome","volume":"11","author":"Hinske","year":"2010","journal-title":"BMC Genomics"},{"key":"key20180107211143_b39-or-35-02-0614","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.cell.2005.07.031","article-title":"Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation","volume":"122","author":"Bagga","year":"2005","journal-title":"Cell"},{"key":"key20180107211143_b40-or-35-02-0614","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molcel.2008.05.001","article-title":"MicroRNA-10a binds the 5\u2032UTR of ribosomal protein mRNAs and enhances their translation","volume":"30","author":"\u00d8rom","year":"2008","journal-title":"Mol Cell"},{"key":"key20180107211143_b41-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1126\/science.1149460","article-title":"Switching from repression to activation: microRNAs can up-regulate translation","volume":"318","author":"Vasudevan","year":"2007","journal-title":"Science"},{"key":"key20180107211143_b42-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1126\/science.1115079","article-title":"Inhibition of translational initiation by let-7 MicroRNA in human cells","volume":"309","author":"Pillai","year":"2005","journal-title":"Science"},{"key":"key20180107211143_b43-or-35-02-0614","doi-asserted-by":"crossref","first-page":"e1000238","DOI":"10.1371\/journal.pbio.1000238","article-title":"Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA","volume":"7","author":"Hendrickson","year":"2009","journal-title":"PLoS Biol"},{"key":"key20180107211143_b44-or-35-02-0614","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/embor.2010.44","article-title":"microRNA\/Argonaute 2 regulates nonsense-mediated messenger RNA decay","volume":"11","author":"Choe","year":"2010","journal-title":"EMBO Rep"},{"key":"key20180107211143_b45-or-35-02-0614","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1752-0509-5-19","article-title":"Modeling RNA interference in mammalian cells","volume":"5","author":"Cuccato","year":"2011","journal-title":"BMC Syst Biol"},{"key":"key20180107211143_b46-or-35-02-0614","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF03256383","article-title":"Exploiting the therapeutic potential of microRNAs in viral diseases: Expectations and limitations","volume":"14","author":"Hemida","year":"2010","journal-title":"Mol Diagn Ther"},{"key":"key20180107211143_b47-or-35-02-0614","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-10-2010","article-title":"The promise of microRNA replacement therapy","volume":"70","author":"Bader","year":"2010","journal-title":"Cancer Res"},{"key":"key20180107211143_b48-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1056\/NEJMp058190","article-title":"MicroRNAs as oncogenes and tumor suppressors","volume":"353","author":"Chen","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107211143_b49-or-35-02-0614","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"key":"key20180107211143_b50-or-35-02-0614","doi-asserted-by":"crossref","first-page":"e7826","DOI":"10.1371\/journal.pone.0007826","article-title":"MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia","volume":"4","author":"Zhang","year":"2009","journal-title":"PLoS One"},{"issue":"13","key":"key20180107211143_b51-or-35-02-0614","article-title":"The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer","volume":"5","author":"Labbaye","year":"2012","journal-title":"J Hematol Oncol"},{"key":"key20180107211143_b52-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107211143_b53-or-35-02-0614","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2007-07-098749","article-title":"MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia","volume":"111","author":"Garzon","year":"2008","journal-title":"Blood"},{"issue":"10","key":"key20180107211143_b54-or-35-02-0614","article-title":"Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia","volume":"2","author":"Gimenes-Teixeira","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"key20180107211143_b55-or-35-02-0614","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1182\/blood-2008-01-133355","article-title":"MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia","volume":"111","author":"Jongen-Lavrencic","year":"2008","journal-title":"Blood"},{"issue":"7","key":"key20180107211143_b56-or-35-02-0614","article-title":"MicroRNAs in B cell development and malignancy","volume":"5","author":"Fernando","year":"2012","journal-title":"J Hematol Oncol"},{"key":"key20180107211143_b57-or-35-02-0614","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107211143_b58-or-35-02-0614","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"key20180107211143_b59-or-35-02-0614","article-title":"Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia","volume":"3","author":"Xu","year":"2014","journal-title":"Exp Hematol Oncol"},{"key":"key20180107211143_b60-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2174\/13894501113149990185","article-title":"Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells","volume":"14","author":"Seca","year":"2013","journal-title":"Curr Drug Targets"},{"key":"key20180107211143_b61-or-35-02-0614","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers","volume":"101","author":"Calin","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107211143_b62-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1158\/1541-7786.MCR-08-0167","article-title":"Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth","volume":"6","author":"Agirre","year":"2008","journal-title":"Mol Cancer Res"},{"key":"key20180107211143_b63-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood-2014-06-581926","article-title":"MicroRNA-486 regulates normal eryth-ropoiesis and enhances growth and modulates drug response in CML progenitors","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"key20180107211143_b64-or-35-02-0614","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ijc.28043","article-title":"Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem\/progenitor cells","volume":"133","author":"Babashah","year":"2013","journal-title":"Int J Cancer"},{"key":"key20180107211143_b65-or-35-02-0614","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","article-title":"Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells","volume":"109","author":"Venturini","year":"2007","journal-title":"Blood"},{"key":"key20180107211143_b66-or-35-02-0614","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.cell.2010.01.007","article-title":"miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts","volume":"140","author":"Eiring","year":"2010","journal-title":"Cell"},{"key":"key20180107211143_b67-or-35-02-0614","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood-2007-03-078303","article-title":"High levels of the BCR\/ABL oncoprotein are required for the MAPK-hnRNP E2 dependent suppression of C\/EBPalpha-driven myeloid differentiation","volume":"110","author":"Chang","year":"2007","journal-title":"Blood"},{"key":"key20180107211143_b68-or-35-02-0614","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ng791","article-title":"BCR-ABL suppresses C\/EBPalpha expression through inhibitory action of hnRNP E2","volume":"30","author":"Perrotti","year":"2002","journal-title":"Nat Genet"},{"issue":"41","key":"key20180107211143_b69-or-35-02-0614","article-title":"Expression patterns of microRNAs associated with CML phases and their disease related targets","volume":"10","author":"Machov\u00e1 Pol\u00e1kov\u00e1","year":"2011","journal-title":"Mol Cancer"},{"key":"key20180107211143_b70-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","article-title":"Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia","volume":"95","author":"Flamant","year":"2010","journal-title":"Haematologica"},{"key":"key20180107211143_b71-or-35-02-0614","doi-asserted-by":"crossref","first-page":"e35501","DOI":"10.1371\/journal.pone.0035501","article-title":"Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells","volume":"7","author":"Rokah","year":"2012","journal-title":"PLoS One"},{"key":"key20180107211143_b72-or-35-02-0614","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12079-011-0139-x","article-title":"MicroRNAs 130a\/b are regulated by BCR-ABL and down-regulate expression of CCN3 in CML","volume":"5","author":"Suresh","year":"2011","journal-title":"J Cell Commun Signal"},{"key":"key20180107211143_b73-or-35-02-0614","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2015.02.031","article-title":"Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment","volume":"360","author":"Hershkovitz-Rokah","year":"2015","journal-title":"Cancer Lett"},{"key":"key20180107211143_b74-or-35-02-0614","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/ijlh.12351","article-title":"Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"37","author":"Fallah","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"key20180107211143_b75-or-35-02-0614","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","volume":"4","author":"Bhamidipati","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"key20180107211143_b76-or-35-02-0614","doi-asserted-by":"crossref","first-page":"12481","DOI":"10.1073\/pnas.0605298103","article-title":"NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses","volume":"103","author":"Taganov","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107211143_b77-or-35-02-0614","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1158\/1535-7163.MCT-07-0305","article-title":"IkappaB kinase beta inhibition induces cell death in imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells","volume":"7","author":"Duncan","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"key20180107211143_b78-or-35-02-0614","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/onc.2012.557","article-title":"BCR-ABL\/GATA1\/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia","volume":"33","author":"Xu","year":"2014","journal-title":"Oncogene"},{"key":"key20180107211143_b79-or-35-02-0614","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FPC.0b013e328350012b","article-title":"MicroRNA profiling in K-562 cells under imatinib treatment: Influence of miR-212 and miR-328 on ABCG2 expression","volume":"22","author":"Turrini","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"key20180107211143_b80-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/leu.2012.65","article-title":"Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells","volume":"26","author":"Yu","year":"2012","journal-title":"Leukemia"},{"key":"key20180107211143_b81-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.leukres.2013.07.019","article-title":"imatinib induces demethylation of miR-203 gene: An epigenetic mechanism of anti-tumor effect of imatinib","volume":"37","author":"Shibuta","year":"2013","journal-title":"Leuk Res"},{"issue":"69","key":"key20180107211143_b82-or-35-02-0614","article-title":"MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations","volume":"8","author":"San Jos\u00e9-En\u00e9riz","year":"2009","journal-title":"Mol Cancer"},{"key":"key20180107211143_b83-or-35-02-0614","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.leukres.2011.03.029","article-title":"MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?","volume":"35","author":"Lopotov\u00e1","year":"2011","journal-title":"Leuk Res"},{"key":"key20180107211143_b84-or-35-02-0614","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.leukres.2011.08.023","article-title":"miRNA-451: A putative predictor marker of imatinib therapy response in chronic myeloid leukemia","volume":"36","author":"Scholl","year":"2012","journal-title":"Leuk Res"},{"key":"key20180107211143_b85-or-35-02-0614","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/mol.110.066258","article-title":"Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: Implications for drug resistance in myelogenous leukemia","volume":"78","author":"Zimmerman","year":"2010","journal-title":"Mol Pharmacol"},{"key":"key20180107211143_b86-or-35-02-0614","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.bbrc.2012.07.098","article-title":"Myc induced miR-144\/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562","volume":"425","author":"Liu","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107211143_b87-or-35-02-0614","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bgm.2013.07.002","article-title":"Identification of nilotinib-altered microRNA expression patterns in imatinib-resistant chronic myeloid leukemia cells","volume":"5","author":"You","year":"2013","journal-title":"Biomark Genomic Med"},{"key":"key20180107211143_b88-or-35-02-0614","first-page":"437","article-title":"miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells","volume":"18","author":"Firatligil","year":"2013","journal-title":"J BUON"},{"issue":"27","key":"key20180107211143_b89-or-35-02-0614","article-title":"Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia","volume":"6","author":"Mosakhani","year":"2013","journal-title":"Mol Cytogenet"},{"key":"key20180107211143_b90-or-35-02-0614","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/DDDT.S66812","article-title":"Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: A possible biomarker to discontinue imatinib safely","volume":"8","author":"Ohyashiki","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"key20180107211143_b91-or-35-02-0614","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3133.3133","volume-title":"Identification of new microRNA biomarkers and candidate target genes in primitive CML cells using global comparative RNA analyses","author":"Lin","year":"2014"},{"key":"key20180107211143_b92-or-35-02-0614","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gene.2014.03.049","article-title":"Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR\/ABL positive CML patients","volume":"542","author":"Joshi","year":"2014","journal-title":"Gene"},{"key":"key20180107211143_b93-or-35-02-0614","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/cas.12339","article-title":"Downregulation of miR-217 correlates with resistance of Ph+ leukemia cells to ABL tyrosine kinase inhibitors","volume":"105","author":"Nishioka","year":"2014","journal-title":"Cancer Sci"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2015.4456\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T18:16:45Z","timestamp":1718216205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2015.4456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,26]]},"references-count":93,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,11,26]]},"published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.3892\/or.2015.4456"],"URL":"https:\/\/doi.org\/10.3892\/or.2015.4456","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,26]]}}}